Philips to Further Expand its Image-Guided Therapy Devices Portfolio through Acquisition of Vesper Medical

PhilipsRoyal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, announced that it has signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that develops minimally-invasive peripheral vascular devices. Vesper Medical will further expand Philips' portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease. The transaction, which is subject to customary closing conditions, is expected to be completed in the first quarter of 2022. Financial details of the transaction were not disclosed.

Philips already has a leading peripheral vascular portfolio, consisting of: live 2D/3D interventional imaging combined with intravascular ultrasound (IVUS) catheters to provide the visualization and guidance essential for the optimal diagnosis and treatment; peripheral atherectomy devices to remove blockages; and peripheral therapy devices, including the Stellarex drug-coated balloon to treat lesions, and the Tack implantable dissection repair device that restores blood flow in small limb vessels, which Philips added to its offering through the acquisition of Intact Vascular in 2020. With this portfolio, Philips provides clinicians with a complete procedural solution for the treatment of peripheral artery disease (PAD).

Complementing Philips’ strong IVUS offering in venous imaging, Vesper Medical will add a venous stenting solution to address the root cause of chronic deep venous disease (DVD). The Vesper DUO Venous Stent System® consists of venous stents intended to treat deep venous obstruction. Uniquely engineered to address the multiple anatomical challenges of the deep venous system, it provides physicians with a modular portfolio to customize therapy, restore venous flow, and resolve the painful symptoms of deep venous disease for the broad range of patients suffering from chronic venous insufficiency.

"The acquisition of Vesper Medical is another step in our objective to innovate patient treatment with more sophisticated technology and expand our growth in the vascular therapy space," said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. "Leveraging our significant procedural expertise, we see strong clinical synergies between Vesper Medical's innovative stenting solution and our existing peripheral vascular offering. This combined offering will help to better support clinicians to decide, guide, treat and confirm during the procedure, thereby enhancing patient care."

"I am proud that Philips will become the home for our innovations and our people, joining forces to shape the future of treating deep venous disease," said Bruce Shook, President and CEO of Vesper Medical. "I look forward to further advance our next generation venous technology and bring it to patients and clinicians globally, together with Philips."

Vesper Medical was founded in 2016 and is headquartered in Wayne, Pennsylvania, US. Upon completion of the transaction, Vesper Medical and approximately 20 of its employees will become part of Philips' Image-Guided Therapy business.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries.

Most Popular Now

AI Points the Way to Better Doctor-Patie…

A computer analysis of hundreds of thousands of secure email messages between doctors and patients found that most doctors use language that is too complex for their patients to understand...

Open Call DIGITAL-2021-DEPLOY-01-TWINS-H…

The development of digital twins in healthcare (DTH) has progressed substantially, profiting from advances in science and technology. In order to exploit their benefits in view of better prevention approaches...

Mayo Clinic Researchers Use AI, Biomarke…

Treatment options for rheumatoid arthritis have often relied on trial and error. Now Mayo Clinic researchers are exploring the use of artificial intelligence (AI) and pharmacogenomics to predict how patients...

Mjog by Livi Launches Remote Monitoring …

Mjog by Livi has launched a remote monitoring tool that will help GPs support and monitor people with depression through messages sent to their smartphones. The latest data from the Office...

Could EKGs Help Doctors use AI to Detect…

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI)...

Computer Model of Blood Enzyme

Membrane-associated proteins play a vital role in a variety of cellular processes, yet little is known about the membrane-association mechanism. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein with an...

4.5 Million Euros in EU Funding for Saar…

This year, three computer scientists from Saarbrücken were awarded an "ERC Starting Grant" by the European Research Council. This award, endowed with 1.5 million euros each, is among the most...

2022 EU4Health Work Programme Adopted to…

Today the Commission has adopted the second EU4Health work programme. In 2022, the EU4Health will continue to invest in building stronger, more resilient health systems and pave the way for...

Five NHS Trusts in Surrey and Sussex to …

A consortium of NHS trusts that covers a population of circa 1.2 million will gain immediate access to important patient imaging, and will mobilise a regional workforce for patients, following...

Helping Cancer Patients Avoid Excessive …

A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to identify which patients with certain head and neck cancers would benefit from reducing the intensity of...

The Programme for the Union's Action in …

On 24 March 2021, Regulation (EU) 2021/522 of the European Parliament and of the Council1 was adopted as part of the Multiannual Financial Framework for the 2021-2027 period. That Regulation...

CliniSys Acquires HORIZON Lab Systems an…

CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Systems, as CliniSys. This acquisition and Sunquest combination creates one of the world’s...